TY - STD TI - Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 21 Apr 2017. UR - http://globocan.iarc.fr ID - ref1 ER - TY - JOUR AU - Bass, A. J. AU - Thorsson, V. AU - Shmulevich, I. AU - Reynolds, S. M. AU - Miller, M. AU - Bernard, B. PY - 2014 DA - 2014// TI - Comprehensive molecular characterization of gastric adenocarcinoma JO - Nature VL - 513 UR - https://doi.org/10.1038/nature13480 DO - 10.1038/nature13480 ID - Bass2014 ER - TY - JOUR AU - Bilici, A. PY - 2014 DA - 2014// TI - Treatment options in patients with metastatic gastric cancer: current status and future perspectives JO - World J Gastroenterol VL - 20 UR - https://doi.org/10.3748/wjg.v20.i14.3905 DO - 10.3748/wjg.v20.i14.3905 ID - Bilici2014 ER - TY - JOUR AU - Reck, M. AU - Rodríguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csőszi, T. AU - Fülöp, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Cowey, C. L. AU - Lao, C. D. PY - 2015 DA - 2015// TI - Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus Everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Muro, K. AU - Chung, H. C. AU - Shankaran, V. AU - Geva, R. AU - Catenacci, D. AU - Gupta, S. PY - 2016 DA - 2016// TI - Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial JO - The Lancet Oncology VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)00175-3 DO - 10.1016/S1470-2045(16)00175-3 ID - Muro2016 ER - TY - STD TI - Kang Y, Satoh T, Ryu M, Chao Y, Kato K, Chung HC,, et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. J Clin Oncol. 2017;35(suppl 4S; abstract 2). ID - ref8 ER - TY - STD TI - Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181). https://clinicaltrials.gov/ct2/show/NCT02564263?term=NCT02564263&rank=1 UR - https://clinicaltrials.gov/ct2/show/NCT02564263?term=NCT02564263&rank=1 ID - ref9 ER - TY - JOUR AU - Hironaka, S. AU - Ueda, S. AU - Yasui, H. AU - Nishina, T. AU - Tsuda, M. AU - Tsumura, T. PY - 2013 DA - 2013// TI - Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology VL - 31 UR - https://doi.org/10.1200/JCO.2012.48.5805 DO - 10.1200/JCO.2012.48.5805 ID - Hironaka2013 ER - TY - JOUR AU - Fuchs, C. S. AU - Tomasek, J. AU - Yong, C. J. AU - Dumitru, F. AU - Passalacqua, R. AU - Goswami, C. PY - 2014 DA - 2014// TI - Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial JO - Lancet (London, England) VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)61719-5 DO - 10.1016/S0140-6736(13)61719-5 ID - Fuchs2014 ER - TY - JOUR AU - Wilke, H. AU - Muro, K. AU - Van Cutsem, E. AU - Oh, S. C. AU - Bodoky, G. AU - Shimada, Y. PY - 2014 DA - 2014// TI - Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial JO - The Lancet Oncology. VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70420-6 DO - 10.1016/S1470-2045(14)70420-6 ID - Wilke2014 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science (New York, NY) VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - STD TI - Yuasa T, Masuda H, Yamamoto S, Numao N, Yonese J. Biomarkers to predict prognosis and response to checkpoint inhibitors. Int J Clin Oncol. 2017:1–6. ID - ref15 ER - TY - JOUR AU - Diggs, L. P. AU - Hsueh, E. C. PY - 2017 DA - 2017// TI - Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response JO - Biomarker research VL - 5 UR - https://doi.org/10.1186/s40364-017-0093-8 DO - 10.1186/s40364-017-0093-8 ID - Diggs2017 ER - TY - JOUR AU - Wu, C. AU - Zhu, Y. AU - Jiang, J. AU - Zhao, J. AU - Zhang, X. G. AU - Xu, N. PY - 2006 DA - 2006// TI - Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance JO - Acta Histochem VL - 108 UR - https://doi.org/10.1016/j.acthis.2006.01.003 DO - 10.1016/j.acthis.2006.01.003 ID - Wu2006 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Campesato, L. F. AU - Barroso-Sousa, R. AU - Jimenez, L. AU - Correa, B. R. AU - Sabbaga, J. AU - Hoff, P. M. PY - 2015 DA - 2015// TI - Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice JO - Oncotarget VL - 6 ID - Campesato2015 ER - TY - JOUR AU - Li, Y. AU - Zhang, L. AU - Ball, R. L. AU - Liang, X. AU - Li, J. AU - Lin, Z. PY - 2012 DA - 2012// TI - Comparative analysis of somatic copy-number alterations across different human cancer types reveals two distinct classes of breakpoint hotspots JO - Hum Mol Genet VL - 21 UR - https://doi.org/10.1093/hmg/dds340 DO - 10.1093/hmg/dds340 ID - Li2012 ER - TY - STD TI - Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science (New York, NY). 2017;355(6322). doi:10.1126/science.aaf8399. ID - ref21 ER - TY - JOUR AU - Deng, N. AU - Goh, L. K. AU - Wang, H. AU - Das, K. AU - Tao, J. AU - Tan, I. B. PY - 2012 DA - 2012// TI - A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets JO - Gut VL - 61 UR - https://doi.org/10.1136/gutjnl-2011-301839 DO - 10.1136/gutjnl-2011-301839 ID - Deng2012 ER -